Total Payments
$1.3M
2024 Payments
$162,918
Companies
23
Transactions
1,143
Payment Breakdown by Category
Other$579,017 (43.7%)
Research$456,906 (34.5%)
Consulting$171,127 (12.9%)
Travel$86,349 (6.5%)
Food & Beverage$21,784 (1.6%)
Education$9,867 (0.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $488,742 | 203 | 36.9% |
| Unspecified | $456,906 | 117 | 34.5% |
| Consulting Fee | $171,127 | 73 | 12.9% |
| Travel and Lodging | $86,349 | 395 | 6.5% |
| Honoraria | $84,770 | 32 | 6.4% |
| Food and Beverage | $21,784 | 314 | 1.6% |
| Education | $9,867 | 4 | 0.7% |
| Compensation for serving as faculty or as a speaker for a medical education program | $5,505 | 5 | 0.4% |
Payments by Type
General
$868,144
1,026 transactions
Research
$456,906
117 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Supernus Pharmaceuticals, Inc. | $344,692 | 402 | $0 (2024) |
| Tris Pharma Inc | $255,319 | 104 | $0 (2024) |
| Rhodes Pharmaceuticals L.P. | $161,305 | 51 | $0 (2019) |
| Ironshore Pharmaceuticals Inc. | $147,795 | 209 | $0 (2023) |
| Corium, LLC | $93,822 | 79 | $0 (2024) |
| Purdue Pharma L.P. | $79,713 | 13 | $0 (2021) |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $69,921 | 65 | $0 (2024) |
| Shire North American Group Inc | $54,019 | 81 | $0 (2019) |
| Neos Therapeutics, LP | $33,148 | 53 | $0 (2023) |
| Arbor Pharmaceuticals, Inc. | $23,324 | 8 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $162,918 | 175 | Supernus Pharmaceuticals, Inc. ($99,543) |
| 2023 | $140,951 | 136 | Supernus Pharmaceuticals, Inc. ($75,473) |
| 2022 | $128,728 | 110 | Supernus Pharmaceuticals, Inc. ($58,790) |
| 2021 | $194,985 | 127 | Purdue Pharma L.P. ($79,097) |
| 2020 | $33,344 | 45 | Supernus Pharmaceuticals, Inc. ($17,723) |
| 2019 | $188,650 | 314 | Ironshore Pharmaceuticals Inc. ($112,780) |
| 2018 | $89,531 | 119 | Rhodes Pharmaceuticals L.P. ($22,943) |
| 2017 | $385,944 | 117 | Tris Pharma Inc ($191,653) |
All Payment Transactions
1,143 individual payment records from CMS Open Payments — Page 1 of 46
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/09/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Consulting Fee | Cash or cash equivalent | $375.00 | General |
| 12/06/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Food and Beverage | In-kind items and services | $101.45 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 12/06/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Food and Beverage | In-kind items and services | $85.08 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 12/06/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Food and Beverage | In-kind items and services | $55.00 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 12/06/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Food and Beverage | In-kind items and services | $26.57 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 12/06/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Food and Beverage | In-kind items and services | $12.08 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 12/05/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Honoraria | Cash or cash equivalent | $5,990.00 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 12/05/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Honoraria | Cash or cash equivalent | $5,990.00 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 12/05/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Travel and Lodging | In-kind items and services | $617.96 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 12/05/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Travel and Lodging | In-kind items and services | $375.76 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 12/05/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Food and Beverage | In-kind items and services | $200.09 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 12/03/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,593.75 | General |
| 11/25/2024 | Tris Pharma Inc | — | Consulting Fee | Cash or cash equivalent | $6,500.00 | General |
| 10/31/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Travel and Lodging | In-kind items and services | $140.60 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 10/31/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Travel and Lodging | In-kind items and services | $140.60 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 10/30/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Food and Beverage | In-kind items and services | $11.46 | General |
| 10/29/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Honoraria | Cash or cash equivalent | $5,990.00 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 10/29/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Honoraria | Cash or cash equivalent | $5,990.00 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 10/29/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Travel and Lodging | In-kind items and services | $688.62 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 10/29/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Travel and Lodging | In-kind items and services | $688.62 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 10/29/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Travel and Lodging | In-kind items and services | $140.60 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 10/29/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Travel and Lodging | In-kind items and services | $140.60 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 10/28/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Travel and Lodging | In-kind items and services | $526.20 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 10/28/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Travel and Lodging | In-kind items and services | $60.00 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 10/26/2024 | Corium, LLC | Azstarys (Drug) | Food and Beverage | In-kind items and services | $19.44 | General |
| Category: CNS Stimulant for ADHD | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Dynavel XR Extended-Release Oral Suspension in the Treatment of Children with ADHD Al Laboratory School Study | Tris Pharma Inc | $190,146 | 3 |
| Real-world Evidence of Duration of Adhansia XR for treatment of ADHD (REDAX): An open-label pragmatic study to assess the real-world effectiveness of Adhansia XR in treatment of adult and adolescent patients with ADHD in the United States | Purdue Pharma L.P. | $79,097 | 12 |
| RP-BP-EF004 | Rhodes Pharmaceuticals L.P. | $77,078 | 32 |
| RP-BP-EF003 | Rhodes Pharmaceuticals L.P. | $66,765 | 12 |
| Adult Attention Deficit Hyperactivity Disorder ADHD Study With Amphetamine Sulfate | Arbor Pharmaceuticals, Inc. | $17,310 | 4 |
| EF-003 | Rhodes Pharmaceuticals L.P. | $16,704 | 4 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD | Supernus Pharmaceuticals, Inc. | $2,136 | 16 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED TRIAL OF BREXPIPRAZOLE IN TREATMENT OF CHILDREN AND ADOLESCENTS WITH IRRITABILITY ASSOCIATED WITH AUTISM SPECTRUM DISORDER | Otsuka Pharmaceutical Development & Commercialization, Inc. | $1,542 | 7 |
| ACP-103-069_070 | ACADIA Pharmaceuticals Inc | $1,386 | 9 |
| An Open-Label, Single-Dose Pharmacokinetic Study of ADZENYS XR ODT in Male and Female Children 4 to Less Than 6 Years of Age With Attention-Deficit/Hyperactivity Disorder (ADHD) | Neos Therapeutics, LP | $1,374 | 6 |
| A PHASE 4, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN PRESCHOOL-AGE CHILDREN (4 TO 5 YEARS OLD) WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) | Supernus Pharmaceuticals, Inc. | $1,050 | 1 |
| A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE (SPD503) IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER | Takeda Pharmaceuticals U.S.A., Inc. | $907.29 | 8 |
| AR19.004 | Arbor Pharmaceuticals, Inc. | $762.13 | 1 |
| Phase 4 (PMR Pediatric GAD) SCT-MD-60 | Allergan, Inc. | $600.00 | 1 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-AND ACTIVE-CONTROLLEDTRIAL TO EVALUATE THE EFFICACY OF BREXPIPRAZOLE MONOTHERAPY FOR THE TREATMENT IN ADOLESCENTS (13-17 YEARS OLD) WITH SCHIZOPHRENIA | Otsuka Pharmaceutical Development & Commercialization, Inc. | $47.70 | 1 |
About Ann Childress
Ann Childress is a Child & Adolescent Psychiatry healthcare provider based in Las Vegas, Nevada. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/16/2006. The National Provider Identifier (NPI) number assigned to this provider is 1457303828.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Ann Childress has received a total of $1.3M in payments from pharmaceutical and medical device companies, with $162,918 received in 2024. These payments were reported across 1,143 transactions from 23 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($488,742).
Ad
Practice Information
- Specialty Child & Adolescent Psychiatry
- Location Las Vegas, NV
- Active Since 05/16/2006
- Last Updated 07/08/2007
- Taxonomy Code 2084P0804X
- Entity Type Individual
- NPI Number 1457303828
Products in Payments
- Dyanavel XR (Drug) $241,657
- Aptensio XR (Drug) $160,625
- QELBREE (Drug) $143,079
- Jornay PM 20mg capsules (Bottle of 100) (Drug) $112,780
- Qelbree (Drug) $99,543
- ADHANSIA XR (Drug) $96,349
- Azstarys (Drug) $60,417
- MYDAYIS (Drug) $45,598
- JORNAY PM (Drug) $35,015
- AZSTARYS (Drug) $33,406
- Adzenys XR-ODT (Drug) $31,048
- AR19 (Drug) $18,072
- VYVANSE (Drug) $10,136
- QUILLIVANT XR (Drug) $6,400
- Vyvanse (Drug) $5,723
- Xelstrym (Drug) $5,505
- Relexxii (Drug) $5,400
- Evekeo (Drug) $5,252
- TROKENDI XR (Drug) $4,352
- Quillichew ER (Drug) $3,790
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Child & Adolescent Psychiatry Doctors in Las Vegas
Mr. Emmanuel Nwapa, M.d, M.D
Child & Adolescent Psychiatry — Payments: $9,039
Child & Adolescent Psychiatry $9,039
Dr. Fernando Mendez, M.d, M.D
Child & Adolescent Psychiatry — Payments: $249.24
Child & Adolescent Psychiatry $249.24
Michael Tanner, Md, MD
Child & Adolescent Psychiatry — Payments: $112.00
Child & Adolescent Psychiatry $112.00
Dr. Lisa Durette, Md, MD
Child & Adolescent Psychiatry — Payments: $29.95
Child & Adolescent Psychiatry $29.95
Mrs. Robyn Schleifman, Crna, CRNA
Child & Adolescent Psychiatry
Child & Adolescent Psychiatry
Dr. Steve Alcazar, Md, MD
Child & Adolescent Psychiatry
Child & Adolescent Psychiatry